Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 9/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | BDKRB2 | P30411 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alprenolol SCHEMBL29414120 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1LMNAHTR1ASLC6A4 | |
| Alprenolol SCHEMBL34636 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1LMNAHTR1ASLC6A4 | |
| Alprenolol SCHEMBL29355107 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1LMNAHTR1ASLC6A4 | |
| Alprenolol SCHEMBL34637 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1LMNAHTR1ASLC6A4 | |
| Alprenolol SCHEMBL6508231 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1LMNAHTR1ASLC6A4 | |
| Alprenolol SCHEMBL10762606 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1LMNAHTR1ASLC6A4 | |
| Alprenolol SCHEMBL29725600 | 0.99 | LMNA (1.00) | ADRB2ADRB1LMNAHTR1ASLC6A4 | |
| Alprenolol SCHEMBL349102 | 0.99 | LMNA (1.00) | ADRB2ADRB1LMNAHTR1ASLC6A4 | |
| Alprenolol SCHEMBL349100 | 0.99 | LMNA (1.00) | ADRB2ADRB1LMNAHTR1ASLC6A4 | |
| Alprenolol SCHEMBL7692100 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1LMNAHTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637708-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | Novaliq GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| WO-2024133913-A9 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | NOVALIQ GMBH (DE) | 2025-03-20 | — | — | WO | claimed |
| WO-2024133913-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | NOVALIQ GMBH (DE) | 2024-06-27 | — | — | WO | claimed |
| EP-4637708-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | Novaliq GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| WO-2024133913-A9 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | NOVALIQ GMBH (DE) | 2025-03-20 | — | — | WO | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| WO-2024133913-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | NOVALIQ GMBH (DE) | 2024-06-27 | — | — | WO | disclosed |
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | RDE PHARMA | 2022-07-21 | — | — | US | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| US-11254720-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | ON TARGET THERAPEUTICS LLC (US) | 2022-02-22 | — | — | US | disclosed |
| US-20190135882-A1 | Methods and Systems for Designing and/or Characterizing Soluble Lipidated Ligand Agents | ON TARGET THERAPEUTICS LLC | 2019-05-09 | — | — | US | disclosed |
| US-10233219-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | TUFTS MEDICAL CENTER (US) | 2019-03-19 | — | — | US | disclosed |
| US-20160052982-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2016-02-25 | — | — | US | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| CN-103415286-A | Compounds and methods for treating pain | AKRON MOLECULES GMBH | 2013-11-27 | — | — | CN | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | ADRB2 237/4885ADRB1 497/4885LMNA 3003/4885 |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | ADRB2 2941/4885ADRB1 2832/4885LMNA 2571/4885 |
| US-11254720-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | LDLR, HDLBP, LIPG | ADRB2 2941/4885ADRB1 2832/4885LMNA 2571/4885 |
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | PAH, BPGM, TPMT | ADRB2 1682/4885ADRB1 1330/4885LMNA 2689/4885 |
| US-20190135882-A1 | Methods and Systems for Designing and/or Characterizing Soluble Lipidated Ligand Agents | LDLR, HDLBP, LIPG | ADRB2 2941/4885ADRB1 2832/4885LMNA 2571/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | ADRB2 237/4885ADRB1 497/4885LMNA 3003/4885 |
| US-20160052982-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | ADRB2 2941/4885ADRB1 2832/4885LMNA 2571/4885 |
| US-10233219-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | LDLR, HDLBP, LIPG | ADRB2 2941/4885ADRB1 2832/4885LMNA 2571/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | ADRB2 2941/4885ADRB1 2832/4885LMNA 2571/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | ADRB2 1967/4885ADRB1 1777/4885LMNA 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.